Third Joint Conference of the British HIV Association (BHIVA) with the British Association for Sexual Health and HIV (BASHH)

1–4 April 2014

Arena and Convention Centre · Liverpool
Dr John McSorley
North West London Hospitals NHS Trust
Feasibility and acceptability of a quadrivalent human papillomavirus (HPV 4) vaccination programme for young men who have sex with men (MSM)

Results from the first year

Dr John McSorley
North West London Hospitals NHS Trust
HPV4 in young MSM: Background 1

• HPV 6 & 11 associated with anogenital warts
• HPV 16 & 18 with anogenital cancers

• Majority of adult MSM multiply infected
• prevalence range 0 to 20% MSM Teens & 20s

• Lifetime incidence anogenital warts MSM c20%
• Lifetime incidence of anogenital Ca in MSM x15
• x10 again if HIV +ve
HPV4 in young MSM: Background 2

- UK Schools programme HPV4 since Sept 2012
- HPV4 vaccine is immunogenic in MSM (HIV - & +)
- MSM increased risk of bacterial STI acquisition
- MSM acquisition of HIV continues
<table>
<thead>
<tr>
<th>Time (months)</th>
<th>Sexual history, Risk Assessment, STI, Checklist, Support</th>
<th>Hep A &amp; B</th>
<th>HPV4</th>
<th>Time To Test (Text/email)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>1</td>
<td></td>
<td>Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Yes</td>
<td></td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Yes</td>
<td></td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Yes</td>
<td></td>
<td></td>
<td>Yes</td>
</tr>
<tr>
<td>12</td>
<td>Yes</td>
<td></td>
<td></td>
<td>Yes</td>
</tr>
<tr>
<td>ELIGIBLE</td>
<td>n = 256</td>
<td>207 Homosexual</td>
<td>47 Bisexual</td>
<td>2 Transsexual</td>
</tr>
<tr>
<td>--------------------------</td>
<td>---------</td>
<td>----------------</td>
<td>-------------</td>
<td>---------------</td>
</tr>
<tr>
<td>DID NOT START</td>
<td>n = 55</td>
<td>35 Homosexual</td>
<td>20 Bisexual</td>
<td>p = 0.003</td>
</tr>
<tr>
<td>NOT OFFERED</td>
<td>n = 33</td>
<td>20 Bi “no more”</td>
<td>13 No return</td>
<td></td>
</tr>
<tr>
<td>DECLINED</td>
<td>n = 18</td>
<td>10 Not local</td>
<td>6 No reason</td>
<td>2 Anti-vaccine</td>
</tr>
<tr>
<td>ACCEPTED, Deferred did not return</td>
<td>n = 4</td>
<td>172 Homosexual</td>
<td>20 Bisexual</td>
<td>2 Transsexual</td>
</tr>
<tr>
<td>STARTED</td>
<td>n = 201</td>
<td>172 Homosexual</td>
<td>20 Bisexual</td>
<td>2 Transsexual</td>
</tr>
</tbody>
</table>
HPV4: MSM Ethnicity Groupings as %

- White British: 34%
- White Other: 20%
- Mixed: 20%
- Asian: 17%
- Black: 8%
- Any Other: 2%
## HPV4: Outcomes: Hepatitis vaccination

see POSTER 25 P Kuria et al

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Total</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Documented 3+ Hep B vax</td>
<td>162</td>
<td>80</td>
</tr>
<tr>
<td>Documented Hep A vaxxin</td>
<td>171</td>
<td>85</td>
</tr>
</tbody>
</table>
## Results 1 year; HPV4 uptake & return

<table>
<thead>
<tr>
<th></th>
<th>Total N = 201</th>
<th>% of Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dose 1</strong></td>
<td>201</td>
<td>100%</td>
</tr>
<tr>
<td><strong>Dose 2</strong></td>
<td>155</td>
<td>77%</td>
</tr>
<tr>
<td><strong>Dose 3</strong></td>
<td>98 (&lt;60)</td>
<td>49% (&lt;79%)</td>
</tr>
<tr>
<td><strong>TTT visit(s)</strong></td>
<td>78</td>
<td>79%</td>
</tr>
</tbody>
</table>
HPV4: Results at 1 year HPV4 and STIs
(See Poster 229 Brook et al )

<table>
<thead>
<tr>
<th></th>
<th>Bacterial STI diagnosed</th>
<th>% with STI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose 1</td>
<td>72</td>
<td>36%</td>
</tr>
<tr>
<td>Dose 2</td>
<td>26</td>
<td>17%</td>
</tr>
<tr>
<td>Dose 3</td>
<td>14</td>
<td>14%</td>
</tr>
<tr>
<td>TTT visit</td>
<td>14</td>
<td>18%</td>
</tr>
</tbody>
</table>
HPV4: Questionnaire

- 10 question on-line survey

- \( \frac{161}{201} \) (80%) provided email to contact

- \( \frac{83}{161} \) (52%) contactable

- \( \frac{83}{201} \) (41%) eligible

completed it
HPV4: Questionnaire Q1

• How did you hear about the HPV4 vaccine?

• **85%**    A doctor or nurse in the clinic

• **15%**    Knew about it already
HPV4: Questionnaire Q2

• Did you receive enough information on HPV4
  
  • Yes 93%
  • No 7%
  • Comment 11%

• “its sum kind of the most common disease that you can catch during sex”
HPV4: Questionnaire Q3

- Did/Do you have any concerns re HPV4?
  - No 86%
  - Yes 14%

- "Whether it was safe as it was new for me"
- "My parents were worried that it would encourage promiscuity"
HPV4: Questionnaire Q4

- If you didn’t complete, why not?

- 15 (of 47) “non returners” responded
- 6 forgot
- 3 don’t think it’s necessary
- 2 didn’t like the injection
- 3 can’t get back

- 11 (60) “late” “I am coming back”
HPV4: Questionnaire Q6

- Do you think HPV4 for young MSM is a good idea?
  - Yes 99%
  - No 0%
  - Not sure 1%
  - “It seems to be an important health issue that is being overlooked”
HPV4: Questionnaire Q7

• If you had the vaccine are you happy with your decision?

  • Yes 99%
  • No 1%

• “No” said (I regret) “I didn't have the vaccine”
  • (Hmmm yes you did & you had all 3 doses!)
HPV4: Questionnaire Q8

• Would you recommend HPV4 to others?
  
  • Yes        100%
  • No         0%

• “I have done so already”
• “Sure! :) We need to make the world a.. Better place. Right! :)”
HPV4 in young MSM: Conclusion

• An HPV4 vaccination programme in young MSM is feasible and can achieve coverage commensurate with other catch up programmes
• HPV4 vaccination is highly acceptable to and valued by young MSM
• Vaccination can be a useful tool for early engagement of MSM with sexual health services
• Young MSM have high levels of ongoing sexual health and STI prevention needs
HPV4 in young MSM

Thanks to the young MSM of Brent & Harrow
And staff at

The Patrick Clements Centre
Central Middlesex Hospital
&
Department of GUM & HIV
Northwick Park Hospital
Third Joint Conference
of the
British HIV Association (BHIVA)
with the
British Association for Sexual Health and HIV (BASHH)

1–4 April 2014

Arena and Convention Centre · Liverpool
## HPV4: Young MSM

<table>
<thead>
<tr>
<th></th>
<th>Number</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total</strong></td>
<td>201</td>
<td>100</td>
</tr>
<tr>
<td><strong>New to NWLH</strong></td>
<td>118</td>
<td>59</td>
</tr>
<tr>
<td><strong>First GUM Service</strong></td>
<td>77</td>
<td>38</td>
</tr>
<tr>
<td><strong>Once elsewhere</strong></td>
<td>6</td>
<td>3</td>
</tr>
<tr>
<td><strong>Twice elsewhere</strong></td>
<td>11</td>
<td>5</td>
</tr>
<tr>
<td><strong>3+ elsewhere</strong></td>
<td>107</td>
<td>53</td>
</tr>
<tr>
<td><strong>Never had Hep B vaxxn</strong></td>
<td>104</td>
<td>52</td>
</tr>
<tr>
<td><strong>Never had Hep A vaxxn</strong></td>
<td>101</td>
<td>50</td>
</tr>
</tbody>
</table>